Hepatic impairment No dose adjustment is needed in individuals with moderate or moderate (Child-Pugh A or B) hepatic impairment (see portion 5.two). Exposure to midostaurin and its active metabolite CGP62221 is significantly reduced in patients with critical hepatic impairment than that in sufferers with regular hepatic purpose (see segment five. https://oviniq888nfw9.nytechwiki.com/user